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NOVEL BIOMARKERS OF KNEE OSTEOARTHRITIS
IDENTIFIED USING METABOLIC PROFILING
G. Zhai1, R. Wang-Sattler2, D. Hart1, T. Illig2, T.D. Spector1
1King’s Coll. London, London, United Kingdom; 2Inst. of
Epidemiology, Neuherberg, Germany
Purpose: There is a pressing need to develop reliable molecular
biomarkers that can inform on the process of joint destruction in
osteoarthritis (OA). Such biomarkers could aid in drug develop-
ment by identifying fast progressors and early response to therapy.
Recent advance in metabolomics (the quantitative analysis of all
metabolites present within a biological sample) has opened new
avenues for biomarker identiﬁcation. The aim of the study, there-
fore, was to identify serum metabolic biomarkers for OA using a
metabolomics approach.
Methods: 123 knee OA cases and 299 controls were selected
from the TwinsUK cohort. Knee OA was deﬁned as either radio-
graphic, self-reported OA, or total knee joint replacement due to
primary OA. All the subjects were unrelated Caucasian females.
Their frozen serum samples were retrieved and assessed for
targeted metabolite proﬁling using API4000 Q TRAP LC/MS/MS
System (Applied Biosystems, Darmstadt, Germany) equipped with
Schimadzu Prominence LC20AD pump and SIL-20AC auto sam-
pler with AbsoluteIDQTM Kit (Biocrates life sciences AG, Austria).
Results: A total of 163 serum metabolites were assessed and
their concentrations were obtained. The mean of the coefﬁcient of
variation (CV) for the 163 metabolites was 0.07±0.05 and 90%
of the metabolites had a CV of less than 0.10. The ratios of
all pair metabolite concentrations were calculated and tested for
the association with knee OA. Overall 14 ratios were signiﬁcantly
associated with knee OA with p ≤ 1.9×10-6 which was the signif-
icance level after conservative Bonferroni correction. These ratios
were mainly involved in valine and acylcarnitine, namely the ratios
of valine to arginine, glutamine, glycine, histidine, tyrosine, and
dodecanedioyl-L-carnitine, and the ratios of fumaryl-L-carnitine
to propenoyl-L-carnitine, dodecanedioyl-L-carnitine, and lysophos-
phatidylcholine acyl C26:1. The association between these ratios
and knee OA remained strong even after adjustment for age and
BMI.
Conclusions: This is the ﬁrst study reporting the identiﬁcation
of novel OA biomarkers using a metabonomics approach. The
results suggest that amino acid and acylcarnitine metabolic path-
ways involving valine and fumaryl-L-carnitine are implicated in the
development of OA and have potential clinical use as biomarkers.
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IDENTIFICATION OF A NOVEL HTRA1-SUSCEPTIBLE
CLEAVAGE SITE IN HUMAN AGGRECAN: EVIDENCE FOR
THE INVOLVEMENT OF HTRA1 IN AGGRECAN
PROTEOLYSIS IN VIVO
A. Chamberland, E. Wang, A.R. Jones, E.A. Morris,
C.R. Flannery, Z. Yang
Wyeth Res., Cambridge, MA
Purpose: HtrA1 (also called PRSS11) is a member of the High
Temperature Requirement family of serine proteases, deﬁned by
a characteristic trypsin-like serine protease domain and one or
more C-terminal PDZ domains. HtrA1 expression levels are up-
regulated approximately 7-fold in osteoarthritis (OA) and HtrA1
has been shown to degrade critical components of cartilage ex-
tracellular matrix (ECM) in vitro. Here, we investigated the effect
of HtrA1 overexpression on cartilage matrix formation by using
a chondrocyte alginate culture. In addition, we identiﬁed a novel
HtrA1-susceptible cleavage site within the interglobular domain
(IGD) of aggrecan and have generated neoepitope antibodies to
speciﬁcally detect aggrecan degradation products. We examined
the physiological relevance of aggrecan cleavage by HtrA1 in
OA by determining if these neoepitopes are present in cartilage
extracts.
Methods: Wildtype HtrA1 and an inactive HtrA1 mutant (HtrA1-
ASM) were overexpressed in 3-D alginate cultures of human pri-
mary chondrocytes. Total sulfated glycosaminoglycan (sGAG) was
measured by DMMB assay. Puriﬁed human aggrecan or recom-
binant aggrecan proteins comprised of either the G1-IGD-G2 or
IGD alone were incubated with recombinant HtrA1 (aa 157-480) or
an inactive HtrA1 mutant (aa 157-480, ASM). Cleavage products
were analyzed by N-terminal sequencing. Polyclonal neoepitope
antibodies, which speciﬁcally recognize the cryptic termini of ag-
grecan fragments (but not intact aggrecan), were generated and
characterized by Western blotting. Conditioned media from human
cartilage explants treated with HtrA1 and human cartilage protein
extracts from human donors were subjected to Western blot analy-
sis using one of the neoepitope antibodies. Immunohistochemistry
was used to determine the localization of HtrA1-mediate aggrecan
cleavage in OA cartilage.
Results: Overexpression of wild-type HtrA1, but not the inactive
mutant, caused a marked reduction of total proteoglycan content in
chondrocyte-seeded alginate cultures. Incubation of recombinant
aggrecan proteins with HtrA1 resulted in distinct cleavage of these
substrates. N-terminal sequencing identiﬁed the HtrA1-speciﬁc
cleavage site as VQVT356−357TWPD within the aggrecan IGD.
Western blot analysis of conditioned media from cartilage explants
revealed that a neoepitope-speciﬁc cleavage product was released
when the explants were treated with HtrA1, with or without the in-
clusion of a peptide agonist (CPII), but not when treated with ASM
or ADAMTS-4. To determine whether HtrA1 cleavage of aggrecan
occurs physiologically in OA cartilage, Western blot analysis was
performed on human cartilage protein extracts from 7 patients with
OA and 7 age-matched donors. HtrA1-generated aggrecan frag-
ments were signiﬁcantly more abundant in osteoarthritic cartilage
compared to cartilage from healthy joints. Immunohistochemistry
demonstrated the HtrA1-mediate cleavage of aggrecan occurs
mainly in the surface layer of cartilage where matrix degradation
typically initiates in OA
Conclusions: HtrA1 has been shown to be upregulated in OAcar-
tilage and may play a role in disease progression by breaking
down extracellular matix proteins. Here, we show HtrA1 is ca-
pable of digesting aggrecan and have identiﬁed a novel HtrA1-
susceptible cleavage site. Using a newly generated neoepitope
antibody, we show that HtrA1-generated aggrecan fragment is
more abundant in cartilage from human OA patients relative to
normal donors, suggesting that HtrA1-mediated digestion of ag-
grecan is a physiological relevant event that could contribute to
OA disease progression.
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